189 related articles for article (PubMed ID: 35074471)
1. Value of liver biopsy in the diagnosis of drug-induced liver injury.
Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
[TBL] [Abstract][Full Text] [Related]
2. A revised electronic version of RUCAM for the diagnosis of DILI.
Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.
Molleston JP; Fontana RJ; Lopez MJ; Kleiner DE; Gu J; Chalasani N;
J Pediatr Gastroenterol Nutr; 2011 Aug; 53(2):182-9. PubMed ID: 21788760
[TBL] [Abstract][Full Text] [Related]
4. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M; Kleiner DE; Goodman Z; Brunt E; Avigan MI; Regev A; Hayashi PH; Lewis JH; Mehta R; Harrison SA; Siciliano M; McWherter CA; Vuppalanchi R; Behling C; Miller V; Chalasani N; Sanyal AJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):201-216. PubMed ID: 37877759
[TBL] [Abstract][Full Text] [Related]
5. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
Fontana RJ; Watkins PB; Bonkovsky HL; Chalasani N; Davern T; Serrano J; Rochon J;
Drug Saf; 2009; 32(1):55-68. PubMed ID: 19132805
[TBL] [Abstract][Full Text] [Related]
6. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N; Li YJ; Dellinger A; Navarro V; Bonkovsky H; Fontana RJ; Gu J; Barnhart H; Phillips E; Lammert C; Schwantes-An TH; Nicoletti P; Kleiner DE; Hoofnagle JH;
J Hepatol; 2023 Feb; 78(2):293-300. PubMed ID: 36152763
[TBL] [Abstract][Full Text] [Related]
7. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
[TBL] [Abstract][Full Text] [Related]
8. When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network.
Barritt AS; Barnhart H; Gu J; Dellinger A; Rudnick S; Bonkovsky HL;
Am J Gastroenterol; 2023 Dec; 118(12):2301-2304. PubMed ID: 37311048
[TBL] [Abstract][Full Text] [Related]
9. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Chalasani N; Bonkovsky HL; Fontana R; Lee W; Stolz A; Talwalkar J; Reddy KR; Watkins PB; Navarro V; Barnhart H; Gu J; Serrano J;
Gastroenterology; 2015 Jun; 148(7):1340-52.e7. PubMed ID: 25754159
[TBL] [Abstract][Full Text] [Related]
10. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
11. Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record.
Yeboah-Korang A; Louissaint J; Tsung I; Prabhu S; Fontana RJ
Drug Saf; 2020 Apr; 43(4):371-377. PubMed ID: 31916081
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
13. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Chalasani N; Bonkovsky HL; Stine JG; Gu J; Barnhart H; Jacobsen E; Björnsson E; Fontana RJ; Kleiner DE; Hoofnagle JH;
J Hepatol; 2022 Apr; 76(4):832-840. PubMed ID: 34953957
[TBL] [Abstract][Full Text] [Related]
15. Significant Medical Comorbidities Are Associated With Lower Causality Scores in Patients Presenting With Suspected Drug-Induced Liver Injury.
Ghabril M; Gu J; Yoder L; Corbito L; Dakhoul L; Ringel A; Beyer CD; Vuppalanchi R; Barnhart H; Hayashi PH; Chalasani N
Clin Transl Gastroenterol; 2020 Apr; 11(4):e00141. PubMed ID: 32251016
[TBL] [Abstract][Full Text] [Related]
16. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN).
Hayashi PH; Barnhart HX; Fontana RJ; Chalasani N; Davern TJ; Talwalkar JA; Reddy KR; Stolz AA; Hoofnagle JH; Rockey DC
Liver Int; 2015 May; 35(5):1623-32. PubMed ID: 24661785
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience.
Ghabril M; Fontana R; Rockey D; Jiezhun G; Chalasani N
J Clin Gastroenterol; 2013 Jul; 47(6):553-8. PubMed ID: 23388845
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
Xu HM; Chen Y; Xu J; Zhou Q
World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
[TBL] [Abstract][Full Text] [Related]
19. How to Diagnose and Exclude Drug-Induced Liver Injury.
Watkins PB
Dig Dis; 2015; 33(4):472-6. PubMed ID: 26159261
[TBL] [Abstract][Full Text] [Related]
20. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
Teschke R; Méndez-Sánchez N; Eickhoff A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
